Compare STZ & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STZ | ROIV |
|---|---|---|
| Founded | 1945 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6B | 23.2B |
| IPO Year | 1994 | 2021 |
| Metric | STZ | ROIV |
|---|---|---|
| Price | $132.52 | $35.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 9 |
| Target Price | ★ $175.63 | $28.94 |
| AVG Volume (30 Days) | 1.8M | ★ 4.5M |
| Earning Date | 04-08-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,139,000,000.00 | $8,260,000.00 |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $1.93 | $744.61 |
| P/E Ratio | $24.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $126.45 | $10.90 |
| 52 Week High | $174.32 | $37.00 |
| Indicator | STZ | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 53.92 |
| Support Level | $127.80 | $33.56 |
| Resistance Level | $135.09 | $35.70 |
| Average True Range (ATR) | 2.34 | 1.19 |
| MACD | 0.45 | -0.14 |
| Stochastic Oscillator | 56.17 | 67.60 |
Constellation Brands is the largest provider of alcoholic beverages across the beer, wine, and spirits categories in the US, generating more than 90% of revenue from Mexican beer imports under top-selling brands such as Modelo and Corona. The rest of the business includes some remaining wine and spirits brands, categories where the company has pruned assets in recent years. With its exclusive rights tied to the Mexican beer brands effective only in the US, the firm has limited revenue exposure to international markets. Constellation owns a 10% stake in Canopy Growth, a medicinal and recreational cannabis producer in Canada, and has a 50/50 joint venture with glass manufacturer Owens-Illinois in Mexico.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.